January Emerging Medical Technologies Report

Published January 2013 | 14 Pages | 27 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 27 emerging medical technology companies that have been identified by LSI's in-house research team in January 2013.

All companies include technology, market(s), key executive, and contact information.

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


•1-Drugs to treat cancer and infectious disease using chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered and 2-A cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity
•A fully integrated, disposable strip and adaptor device that, when combined with a smartphone, has the potential to replace existing self-powered glucose meters and increase patient usage
•A specialty diagnostics laboratory with a growing menu of proprietary, internally developed tests focused on rheumatology for more accurate, efficient diagnosis and better disease management
•Bioresorbable implants for bone and tissue regeneration
•Blood tests for the early detection of breast cancer, ovarian cancer, lung cancer, Alzheimer's, and other serious diseases where significant unmet clinical needs exist
•Circulating tumor cell (CTC) technology to provide more frequent and effective monitoring of cancer progression by proactively measuring tumor biology and intelligently adjusting therapy as necessary throughout a patient's treatment lifecycle
•Drug-device combination product to address vascular bypass failure in arterio-venous graft (AVG), arterio-venous fistula (AVF), peripheral arterial bypass graft (PABG), and coronary artery bypass graft (CABG) procedures
•Drugs that block Cav3.2 for the treatment of neuropathic pain, chemotherapy-induced neuropathy, and tremor
•Drugs to treat serious neurological and psychiatric diseases, for which no other treatment exists, such as Tourette syndrome (TS) and Lesch-Nyhan syndrome (LNS)
•Endovascular stapling device that will offer physicians a new treatment option for treating peripheral artery disease (PAD)
•Medical rehabilitation anti-gravity treadmill that provides accurate, safe, and comfortable partial weight-bearing therapy while promoting normal gait patterns
•Microfluidic technology that offers an alternative to painful and invasive biopsies by capturing rare circulating tumor cells (CTC) from whole blood
•Minimally invasive devices for transcatheter mitral valve replacement/repair
•New generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies that will significantly extend the clinical impact of current oncology therapeutic approaches
•New wheelchair wheels that are twice as easy to push as the standard and can be added on to most existing wheelchair frames
•Non-invasive prenatal/first-trimester microarray test that finds small amounts of genetic material that traditional testing such as karyotyping cannot detect
•Non-invasive, non-radiogenic breast health screening device that is able to discover problems at stages far earlier than any other accepted screening methodology
•Novel Toll-like receptor 8 (TLR8) therapeutics for the treatment of cancer, respiratory, and autoimmune diseases
•Ocular drug delivery technologies
•Platform of gamma-secretase modulators for the prevention of neurodegenerative conditions, such as Alzheimer's Disease (AD)
•Real-time, 3-D imaging of internal organs and tissues during surgical procedures such as laparoscopy and arthroscopy, enabling surgeons to remove diseased tissue without damaging healthy neighboring tissue
•Small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders
•Small molecule therapeutics to treat hemoglobin disorders
•Software and associated services that allow clinicians to translate DNA sequence data into verified biomarkers
•Suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis
•Technologies designed to achieve positive outcomes for people with upper limb deficiencies, including: 1-electronic prosthetic hands and fingers and 2-passive silicone prostheses that can match the skin tone/contours of natural fingers, hands, and entire arms
•The SENSIMED Triggerfish(R) "eye-Holter" is a paradigm-changing technology consisting of a disposable contact lens telemetric sensor, which for the first time provides ophthalmologists with the full ambulatory 24-hour IOP profile, conveniently and during uninterrupted daily activities and sleep

Accelerate your business

We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.